Innovating Bioprocess for
Animal Therapeutics Production

We Develop

Novel low COGS antibody expression systems

Low COGS antibody purification technology

Standard Bioprocess Doesn't Meet Veterinary Economics

Animal health is adopting more advanced medicines. And increasingly, biology is not the barrier to getting these drugs to market; manufacturing costs are.

160 approved antibodies for human vs only 5 for animals — antibodies are a clear example where standard methods work, but the result is too expensive to reach veterinary potential.

IgG — CHO works, but the COGS may not

Even with the right yields, CHO is slow, complex and costly to run, with capital expenditure that few can justify.

Gemini_Generated_Image_yotn0ryotn0ryotn_

Complex VHH — Pichia hits a ceiling

Optimised for simple VHH, Pichia's yields fall away on the more complex formats, and the economics fall with them.

Affinity purification — requires costly beads

Purification leans on agarose resins built for human pharma — the single biggest cost in the step.

selection_spp_tree (1)_edited_edited_edi

We mapped 1,200+ yeast species to solve the COGS problem

of antibody production.

Technology

Specific Problem
x
Specific Novel Yeast Species

Upstream:

We start from the molecule, not the host.

Define what an antibody – or any other molecule – needs in order to be made well, then find the yeast species that already meets most of those needs naturally. Only then do we make genetic tools and modify them.

Less engineering, healthier host, better output.

Downstream:

A separately designed and patent-pending technology enables the low-COGS affinity purification.